ClinicalTrials.gg
Not yet recruitingNCT07424495ACEITA3DUpdated Feb 24, 2026

Chewable Tablets Produced by Three-Dimensional Printing: A Sensory Acceptability Study in Children and Adolescents

An observational study in Palatability Assessment of 3D-printed Chewable Tablets in Children and Adolescents, sponsored by University of Brasilia. Not yet recruiting. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by University of Brasilia · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
100
Ages
3 Years to 18 Years
Sex
All
01

Study summary

The lack of appropriate pediatric formulations compromises adherence and the effectiveness of oral treatment in children, mainly due to the splitting of adult tablets and low sensory acceptability. This observational, analytical, and cross-sectional study aims to evaluate the acceptability of a novel pediatric dosage form consisting of placebo chewable tablets produced by 3D printing, with a focus on palatability and feasibility for dose personalization. Children and adolescents aged 3 to 18 years receiving care at the Nutrition Outpatient Clinic of the Hospital da Criança de Brasília José Alencar will be invited to participate. The study will be conducted in two stages. In the first stage, acceptability of a bear-shaped chewable tablet will be assessed, as well as preference among different flavors. In the second stage, preference for chewable tablets with or without xylitol will be investigated, in addition to dysgeusia associated with diseases or chronic medication use. Acceptability will be measured using a 5-point facial hedonic scale, evaluator observation, and age-appropriate questionnaires. The study is expected to identify the most accepted flavors and sweetness intensities, as well as to evaluate the acceptability of the 3D-printed dosage form, contributing to the development of safer, more attractive, and personalized pediatric medicines.

02

Conditions studied

  • Palatability Assessment of 3D-printed Chewable Tablets in Children and Adolescents

Keywords

  • Palatability
  • 3D Printing
  • Chewable Tablet
  • Pediatric Formulation
  • Sensory Acceptability
  • Pharmaceutical Technology
03

In context

Lead sponsor

University of Brasilia is the lead sponsor of 66 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Children and adolescents receiving care at the Nutrition Outpatient Clinic of the Hospital da Criança de Brasília José Alencar.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents aged 3 to 18 years receiving care at the Nutrition Outpatient Clinic of the Hospital da Criança de Brasília José Alencar (HCB).
  • Written provided by the legal guardian through the signing of the Informed Consent Form (ICF).
  • Assent from the child or adolescent, when applicable, expressed through the signing of the Informed Assent Form (IAF).

Exclusion criteria

Exclusion Criteria:

  • Children or adolescents with dietary restrictions or known allergies to any component present in the formulations used in the study.
  • Children or adolescents with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  • Children or adolescents diagnosed with severe neurological, cognitive, or behavioral disorders that impair communication, comprehension, or response to the sensory scale.
  • Oral conditions, mucosal lesions, or dysphagia that prevent or significantly impair proper chewing or swallowing of the tablet (e.g., mucositis).
  • Refusal of the child/adolescent or legal guardian to participate in the study at any time, even after prior consent has been provided.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Target follow-up
2 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Sensory acceptability score (5-point facial hedonic scale)

    Sensory acceptability will be assessed using a 5-point Facial Hedonic Scale ranging from 1 (disliked very much) to 5 (liked very much), with higher scores indicating better acceptability.

    Time frame: Immediately after tablet administration (single assessment per stage)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Lajoinie A, Janiaud P, Henin E, Gleize J-C, Berlion C, Nguyen KA, Nony P, Gueyffier F, Maucort-Boulch D, Kassaï Koupaï B. Assessing the effects of solid versus liquid dosage forms of oral medications on adherence and acceptability in children. Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD012783. DOI: 10.1002/14651858.CD012783.
  • Abdel-Rahman SM, Bai S, Porter-Gill PA, Goode GA, Kearns GL. A Pilot Comparison of High- Versus Low-Tech Palatability Assessment Tools in Young Children. Paediatr Drugs. 2021 Jan;23(1):95-104. doi: 10.1007/s40272-020-00430-2. Epub 2020 Nov 25. PubMed 33236188 ↗
  • Mistry P, Stirling H, Callens C, Hodson J, Batchelor H; SPaeDD-UK project. Evaluation of patient-reported outcome measurements as a reliable tool to measure acceptability of the taste of paediatric medicines in an inpatient paediatric population. BMJ Open. 2018 Jul 11;8(7):e021961. doi: 10.1136/bmjopen-2018-021961. PubMed 29997143 ↗
  • van Riet-Nales DA, de Neef BJ, Schobben AF, Ferreira JA, Egberts TC, Rademaker CM. Acceptability of different oral formulations in infants and preschool children. Arch Dis Child. 2013 Sep;98(9):725-31. doi: 10.1136/archdischild-2012-303303. Epub 2013 Jul 13. PubMed 23853004 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07424495
Lead sponsor
University of Brasilia
Collaborators
Hospital da Criança de Brasília José Alencar
Responsible party
Marcílio Sérgio Soares da Cunha Filho (Doctor, University of Brasilia) — Principal investigator
First posted
Feb 20, 2026
Start date
Mar 2027 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Feb 24, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion